Latest news with #N
Sunday World
2 days ago
- Sunday World
Woman (38) caught with over €4k worth of drugs including an ‘exotic substance'
Defence barrister, Mr Garnet Orange, SC said at the time of the offence, Candice Faulkner Faulkner was an advocate for the cannabis use. A Donegal woman has appeared in court after being caught with over €4,000 worth of drugs, including an 'exotic substance.' Candice Faulkner (38) of Marion Park, Buncrana appeared at Letterkenny Circuit Court before Judge John Aylmer charged with drugs offences. She is charged with possession of a controlled drug, namely cannabis, for unlawful sale or supply at Marion Park on December 28, 2020. Additionally, she is also charged with possessing cannabis resin for the purpose of unlawful sale or supply to another on the same date and location. Faulkner is also charged with possessing N,N-Dimethyltryptamine for the purpose of unlawful sale or supply to another on the same date and location. Garda Declan O'Brien and State Prosecutor Fiona Crawford BL outlined the details of the case and said a search warrant was obtained to search Faulkner's property in December 2020. Faulkner was not present at the time of the search on December 28, 2020 but she returned to the house while the gardaí were there. Candice Faulkner. Photo: Northwest News Pix News in 90 Seconds - 7th June The court heard that cannabis, cannabis resin and N,N-Dimethyltryptamine (N N DMT) were found at the property. Faulkner made full admissions to owning the cannabis while scales, jars and various other items were also found in the property. The court heard Faulkner had previous convictions but they related to traffic matters. Defence barrister, Mr Garnet Orange, SC said at the time of the offence, Faulkner was an advocate for the cannabis use. The cannabis found was 87.7 grams valued at €1,754 while the 289grams of cannabis resin was valued at €1,735.80. However, the court heard it was difficult to put a value on the other plant material but it was valued at €620. In relation to the N,N-Dimethyltryptamine (N N DMT), the court heard a 'strange' red bark material and is a hallucinogenic. Mr Orange referred to the substance as 'eye catching' and an 'exotic substance'. He added there was a difficulty in identifying what it was and placing an evaluation on the substance. Mr Orange said when Faulkner was asked about the substance, she 'didn't have a clue about it' and he said it was found on top of the wardrobe and was covered in dust. The court heard there was a process to distil the hallucinogenic and there was no evidence to suggest that this process was carried out. Mr Orange said Faulkner is a long time cannabis user who uses it in the context of ADHD and she is not out selling drugs on the street. He said the emphasis should be on supply rather than sale. Judge John Aylmer questioned about the other items found at the house and Mr Orange said Faulkner would measure out her own consumption before use and the drugs were for personal use while she also denies that a tick list had anything to do with her. The court heard Faulkner is keen to stop using and is no longer an advocate for cannabis use. Mr Orange asked Judge John Aylmer to deal with the case by a suspended sentence and asked for a probation report to be completed on his client. Judge John Aylmer approved the request for a probation report and ordered it to include an assessment for suitability for community service. The case was adjourned to the October session of the Letterkenny Circuit Court.
Yahoo
14-05-2025
- Entertainment
- Yahoo
Bride Has Bridesmaid Photos Retaken, Leaving Out 'Super Tall' Friend Who Didn't Strictly Follow the Dress Code
A new bride shared on Reddit that she retook her bridesmaid photos at her wedding without one of the women because she "was throwing them all off" She said the one bridesmaid "really stood out" in the photos because she is "super tall and has a muscular build" and also didn't strictly follow the dress code The bridesmaid later got upset when the bride posted 30 wedding photos on Facebook, none of which included her A new bride is wondering if she was in the wrong for retaking her bridesmaid photos without one of the women because she "was throwing them all off." She detailed the dilemma in a post on Reddit's "Am I the A------" forum, explaining that she got married two weeks ago and had six bridesmaids. She said one of the bridesmaids — whom she referred to as "N" — is "super tall and has a muscular build." "She was also wearing a patterned dress when I specifically asked all my bridesmaids to wear solid colors (they got to pick their own dresses and just had to match the color I picked ahead of time)," she noted, adding, "So between the dress and her build, N really stood out in the photos and was throwing them all off." According to the bride, she wasn't the only one who shared that opinion. "After the first round of pictures, we all gathered around the photographer to see what we had so far, and I swear everyone had the same thought simultaneously. Of course, nobody said anything because she's our friend and we wouldn't want to be rude," the bride wrote. But to her surprise, N also acknowledged that she stood out in the photos. "[She] turned to me and said, 'I understand if you want to take some without me.' She didn't seem sad or anything and she was even laughing a little," the bride recalled. "So I told her I thought that was a good idea and me and my other bridesmaids retook the photos without her." The bride thought nothing more of it until after the wedding, when she received the final photos from the photographer and decided to post some of her "favorites" on Facebook. "I didn't include any with N since I was only posting like 30 of the absolute best ones," she noted. But soon after posting the photos, the bride received a message from her friend N, expressing "how hurt she was that I didn't post any with her in them and that I took photos without her in the first place." The bride said she apologized to N and also reminded her that she was the one to suggest taking some photos without her. But N didn't accept her apology, instead accusing her of being "a narcissist and selfish." Ever since the heated exchange, the two friends have not spoken. "I'm so confused since she literally told me I could retake them without her. I also don't think it's such a crime for me to want my wedding photos to be perfect. My husband agrees with me," the bride concluded her post, asking fellow Redditors if she was wrong to exclude her friend. In the comments section, readers did not mince words in telling the OP (original poster) that she behaved terribly to N. "Damn, you really are a rather s----- friend. You really told her that her 'build' doesn't match your aesthetic?" one person wrote. "Good on her for calling you on your shallowness." Another said: "She saw how she stood out, and probably suggested taking some pics without her to make an excuse and lighten the mood. Such comments should always be met with a 'of course we're not, you're part of my wedding' comment. Not actually taking new pictures without her, and then showing her these are the ones you prefer." Someone else reminded the OP: "Your bridesmaids are your friends, not props. You don't get to exclude them from pictures because they're 'distracting.' " Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "So having instagrammable pictures and a good aesthetic matters more to you than preserving the memory of the day, which included this friend who spent time and money to be there and support you," the same person added. "Yeah, I wouldn't talk to you again." One reader expressed their sympathy for N having been slighted in such a "hurtful" way. "I've never wanted to give a stranger a hug so badly before. I can't even imagine how N felt when she left your wedding; only to have to scroll through 30 of your 'absolute favourite' photos two weeks later and have her heart broken all over again." Read the original article on People
NDTV
09-05-2025
- Health
- NDTV
Struggling With Alcohol Consumption? Psychedelics Could Offer A Way Out
Psychedelics could be used to help people reduce their alcohol dependence, a new study currently underway has claimed. For people who struggle to control their drinking, excessive alcohol consumption can lead to serious physical, mental and social consequences. Since traditional experiments do not work for most, scientists at the University College London (UCL) have sought alternatives such as psychedelics The researchers are focusing on N,N-dimethyltryptamine (DMT), a fast-acting psychedelic, whose effects kick in almost immediately when administered intravenously. DMT is the active ingredient in the Amazonian brew ayahuasca, which has a long history of ceremonial use in South America. DMT was particularly chosen as it can impact neuroplasticity -- the brain's ability to form new neural connections. This temporary boost could open a window of flexibility, allowing some people to be more open to change. "Excessive drinking is partly driven by alcohol hijacking the brain's built-in motivation and reward system. We are seeking to counteract that with our treatment. DMT has some interesting effects on the plasticity of our brains, so we hope it can help 'rewrite' the reward associations people have with alcohol," said Professor Ravi Das, co-director of UCL's Clinical Psychopharmacology Unit and joint-lead of the study. Study underway The study is currently underway, where volunteers (mostly heavy drinkers) are given DMT, a placebo or active control drugs (two non-hallucinogenic medications already in common use which may impact brain plasticity) at the UCL lab. The study is double-blind, meaning neither the participants nor the researchers know about the substance being administered. They also undergo two MRI scans while watching a movie so that the scientists can examine whether the drug causes lasting changes in brain function. The volunteers will attend follow-up sessions up to nine months later to analyse the impact the intervention has had on them. "If DMT proves effective in helping people reduce their alcohol consumption, particularly for those who have struggled with other treatments, it could pave the way for a new approach to addiction therapy," the study highlighted, according to ScienceAlert. The scientists warned that psychedelics are potent substances and that their effects can be unpredictable. Taking them without caution or a medical prescription could be dangerous.
Yahoo
08-05-2025
- Health
- Yahoo
Could psychedelics help you to drink less alcohol? Our new study aims to find out
Psychedelics like LSD and psilocybin (the active ingredient in magic mushrooms) are gaining increasing attention in psychiatry. Studies suggest they may offer therapeutic benefits for conditions such as depression, anxiety, obsessive–compulsive disorder, eating disorders and addiction. Our research team is investigating whether N,N-dimethyltryptamine (DMT), a fast-acting psychedelic, can help people reduce alcohol consumption. Alcohol is the most commonly misused substance in the UK, partly because it is legal, widely available and deeply ingrained in social culture. While many people can enjoy alcohol in moderation, a significant number struggle to control their drinking. For these people, excessive alcohol consumption can lead to serious physical, mental and social consequences. Traditional treatments don't work for everyone, which is why we're exploring alternatives, such as psychedelics, that might enable people to change their behaviour in a single, transformative experience. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. Join The Conversation for free today. DMT is metabolised rapidly in the body. When administered intravenously, the effects kick in almost immediately, typically within one to two minutes. However, these effects are short-lived, lasting only ten to 20 minutes. Despite its brief duration, many users describe the experience as intensely profound. They often report vivid visions, complex patterns and a sensation of entering a different reality. In some cases, the experience leads to a complete shift in how they think, feel and perceive the world. For many, the experience is deeply meaningful and transformative. But what happens in the brain during this time, and how might it influence long-term behaviour, such as reducing alcohol consumption? Read more: Our team is particularly interested in how psychedelics like DMT might help in the context of addiction. One theory is that psychedelics can temporarily enhance neuroplasticity, the brain's ability to form new neural connections. This temporary boost could open a window of flexibility, allowing some people to be more open to change. For someone stuck in the cycle of heavy drinking, this enhanced plasticity might help them break old habits and develop healthier behaviour. Essentially, it could offer the brain an opportunity to 'rewire' itself and disrupt the unhealthy patterns that underlie addiction. We're also focusing on the brain's reward and motivation systems, which play a key role in addiction. These systems influence behaviour associated with pleasure, including eating, sex and drinking alcohol. In people with alcohol use disorder, these systems become hypersensitive to alcohol-related cues, often at the expense of other rewarding experiences. Some early research suggests psychedelics may help 'reset' these reward pathways. We're testing this theory to see whether DMT can reduce alcohol consumption by recalibrating the brain's reward system. To explore these possibilities, we've designed a study with heavy drinkers who are motivated to reduce their alcohol intake. Every participant undergoes a thorough screening to ensure they're fit for the study and all sessions are conducted in a highly controlled, clinical setting with medical professionals and experienced researchers overseeing the process. The study involves three visits to our lab at UCL. On the first and third visits, we use functional magnetic resonance imaging (fMRI) to measure brain activity and observe how different regions of the brain interact. During the scans, participants watch emotionally engaging films, which offer a more natural way to study brain responses compared to abstract tasks. This helps us assess how DMT might impact brain function in real-life, emotionally charged situations. On the second visit, participants are randomly assigned to receive either DMT, a placebo, or a non-psychedelic drug (D-cycloserine or Lisuride). These non-psychedelic substances are believed to promote neuroplasticity without inducing the full psychedelic effects of DMT. The study is double-blind – neither the participants nor the researchers know which substance is being administered. This helps eliminate bias and ensures that the results are as reliable as possible. Additionally, we measure changes in brain activity during the drug infusion using electroencephalography (EEG). EEG tracks the brain's electrical signals and could help us predict which participants are most likely to benefit from DMT. Participants also complete a range of psychological assessments, including questionnaires and tasks that measure memory, attention, mood and decision-making. This data will help us understand how changes in brain function might relate to changes in drinking behaviour. We're still in the process of collecting data, but we're excited to see whether DMT can lead to meaningful reductions in alcohol consumption. As researchers, it's crucial that we stay objective and allow the evidence to guide our conclusions. By keeping the study 'blinded' until all results are in, we ensure that our findings are unbiased and reliable. If DMT proves effective in helping people reduce their alcohol consumption, particularly for those who have struggled with other treatments, it could pave the way for a new approach to addiction therapy. Even if the results are inconclusive, they will still provide valuable insights into the potential role of psychedelics in addiction treatment and open up new avenues for future research. It's important to emphasise that this research is taking place in a safe, controlled environment. Psychedelics are potent substances, and their effects can be unpredictable, especially outside of clinical settings. They are not a 'magic bullet' and are not suitable for everyone. The controlled setting allows us to study their effects while minimising risk to participants. That said, we believe psychedelics offer a unique opportunity to better understand the brain and its capacity for change. By examining how transformative experiences can influence behaviour, we hope to contribute to the development of more effective treatments for addiction and other mental health conditions. This article is republished from The Conversation under a Creative Commons license. Read the original article. Ravi Das receives research funding from the Biotechnology and Biological Sciences Research Council (UK), Academy of Medical Sciences (UK) and Wellcome Leap (USA). Rebecca Harding does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Associated Press
17-03-2025
- Business
- Associated Press
Enveric Biosciences Participating in BIO-Europe Spring®
Enveric Biosciences, Inc. (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring ®, which is being held in Milan, Italy, March 17-19, 2025. During the Spring partnering event, members of Enveric's management team are conducting one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones. 'We anticipate a highly productive meeting at BIO-Europe Spring as we continue to garner interest in our strategic approach to developing neuroplastogenic molecules, led by EB-003, for the treatment of underserved mental health conditions. Our ongoing discussions with leaders in the pharmaceutical industry clearly indicate that eliminating or substantially reducing the hallucinatory effect common to N,N-Dimethyltryptamine (DMT), mescaline and related analogs will be key to commercial success,' said Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric. About Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing all other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 [email protected] Relations Tiberend Strategic Advisors, Inc. Casey McDonald (646) 577-8520 INDUSTRY KEYWORD: MENTAL HEALTH HEALTH GENERAL HEALTH RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Enveric Biosciences, Inc. Copyright Business Wire 2025. PUB: 03/17/2025 01:40 PM/DISC: 03/17/2025 01:40 PM
